ONCOLYS BIOPHARMA INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 527 JPY | -1.13% |
|
+6.90% | -7.05% |
Income Statement Evolution (Annual data)
| Fiscal Period: |
|---|
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q1 | 2021 Q3 | 2022 Q1 | 2022 Q3 | 2023 Q1 |
|---|---|---|---|---|---|
| Net sales 1 | 62 | 125 | 193 | 358 | 35 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -349 | -330 | -384 | -279 | -325 |
| Operating Margin | -562.9% | -264% | -198.96% | -77.93% | -928.57% |
| Earnings before Tax (EBT) 1 | -349 | -327 | -328 | -264 | -322 |
| Net income 1 | -350 | -329 | -328 | -265 | -323 |
| Net margin | -564.52% | -263.2% | -169.95% | -74.02% | -922.86% |
| EPS 2 | -22.36 | -18.97 | -18.98 | -15.28 | -18.69 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 07/05/21 | 05/11/21 | 13/05/22 | 04/11/22 | 12/05/23 |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: |
|---|
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -7.05% | 69.65M | |
| +2.87% | 94.22B | |
| -3.42% | 37.76B | |
| -13.75% | 32.5B | |
| +74.52% | 27.75B | |
| -11.88% | 16.13B | |
| +0.49% | 14.19B | |
| -12.95% | 11.42B | |
| +190.36% | 11.06B | |
| -54.07% | 9.09B |
- Stock Market
- Equities
- 4588 Stock
- Financials Oncolys BioPharma Inc.
